Novo Nordisk has appointed a new CEO, Maziar Mike Doustdar, and revised its financial estimates for 2023, forecasting a decline in sales.
Raluca Ioana Draghici
Economy
www.shutterstock.com
Always see our news on Google
Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
21:08
Siegfried Mureșan: I will not resign my mandate if I do not have enough votes for the Government's investiture
20:58
Lily Collins concludes her journey in “Emily in Paris”: “An unreal and bittersweet farewell”
20:51
The Bucharest Stock Exchange closed higher across all indices, while trading reached 348.77 million lei
20:48
Sorin Grindeanu requests an official position from Fitch following an analyst’s warning about the risk of Romania being downgraded to “junk”
20:42
CNAIR has completed excavation work on the “Bear Tunnels” on the A1 motorway
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
The CEO who laid off 900 employees before Christmas is outraged that he has now been fired in turn.
International
AstraZeneca announced the failure of a drug for a rare heart condition, causing a 9% drop in the company's shares.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
